A Patient-Derived 3D Bioprinted Colorectal Cancer-Stroma-Immune Triad Model Uncovers Microenvironmental Mechanisms of Chemoresistance and Immune Evasion

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorPeking Union Medical College Hospital

About this trial

Colorectal cancer (CRC) has shifted toward a patient-personalized precision medicine paradigm; however, the high heterogeneity and complex tumor microenvironment (TME) of CRC restrict the development of individualized therapy, and existing preclinical models and multi-omics technologies are insufficient to broadly benefit patients. Building on previous research, this project intends to use 3D multicellular bioprinting (3DMP) to incorporate key TME components-cancer-associated fibroblasts (CAFs) and PBMC immune cells-to construct patient-derived CRC-CAFs/PBMC 3DMP models, aiming to apply them to personalized clinical drug screening and prognosis prediction, and to combine them with multi-omics technologies to advance preclinical research on CRC. The implementation of this study will help address the bottleneck of the lack of broadly applicable preclinical models for advancing CRC precision therapy. It has major clinical translational value, will bring significant changes to CRC preclinical research platforms, and will help promote the development of cancer precision medicine.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

More than 18 years old

Diagnosed as colorectal cancer with or without liver metastases before

Pathologically proven colorectal cancer after surgery

Disqualifiers

Medical history with other malignancies or serious diseases

Disable to sign the informed consent independently

Trial population

Clinically and pathologically proven colorectal cancer patients are considered as potential candidates of this study. Medical history will be thouroughly taken by clincal practicitioners. Only patients older than 18 years will be included. Those with medical hostory of other malignancies or serious diseases will be excluded. Patients who are not able to sign the informed consent independently will not be included in this study. All the patients included in this study will receive adjuvant/neoadjuvant chemotherapy and surgical resection for the treatment of CRC.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Surgical resection and adjuvant chemotherapy

    Procedure/Surgery

    Surgical resection will be performed for locoregional lesions. Regimens of adjuvant chemotherapy are directed by clinical guidance and experience.

Treatment groups

60 Participants
are divided into 1 treatment group
Group A: Patients with colorectal cancer who underwent surgical resection received adjuvant chemotherapy1 intervention

Trial outcomes

Primary outcomes

1

Response of 3D tumor models/organoids to the same chemotherapy drugs as the corresponding patients.

The investigators will establish and culture 3D colorectal cancer models and organoids. The 3D models and organoids will be treated with the same chemotherapy drugs as the corresponding patients. The viability of the 3D tumor models and organoids will be observed after treatment and the IC50 of each drug will be calculated. The correlation of 3D model/organoid sensitivity and the patient response will be analyzed.

Time frame
2025.05-2026.12

Secondary outcomes

Other outcomes

1

Response of the colorectal cancer patients to adjuvant chemotherapy.

The response to adjuvant chemotherapy will be evaluated according to PFS. Regular follow-ups will be conducted, and PFS is difined as the interval between the date of surgery and the date of last follow-up or recurrence/progression.

Time frame
2025.05-2026.12

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Peking Union Medical College Hospital

Lead sponsor

Ningbo Medical Center Lihuili Hospital

Collaborator